BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock Price & Overview

NASDAQ:BVXV • US09073Q2049

Current stock price

1.36 USD
+0.05 (+3.82%)
At close:
1.38 USD
+0.02 (+1.47%)
After Hours:

The current stock price of BVXV is 1.36 USD. Today BVXV is up by 3.82%. In the past month the price increased by 2.26%. In the past year, price decreased by -87.02%.

BVXV Key Statistics

52-Week Range1.25 - 11.8
Current BVXV stock price positioned within its 52-week range.
1-Month Range1.25 - 1.39
Current BVXV stock price positioned within its 1-month range.
Market Cap
4.967M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-6.86
Dividend Yield
N/A

BVXV Stock Performance

Today
+3.82%
1 Week
N/A
1 Month
+2.26%
3 Months
+0.74%
Longer-term
6 Months -36.69%
1 Year -87.02%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

BVXV Stock Chart

BIONDVAX PHARMACEUTICALS-ADR / BVXV Daily stock chart

BVXV Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BVXV. When comparing the yearly performance of all stocks, BVXV is a bad performer in the overall market: 91.2% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BVXV Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BVXV. Both the profitability and financial health of BVXV have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BVXV Earnings

Next Earnings DateN/A
Last Earnings DateAug 11, 2023
PeriodQ2 / 2023
EPS Reported-$1.11
Revenue Reported
EPS Surprise -19.59%
Revenue Surprise %

BVXV Forecast & Estimates

7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.


Analysts
Analysts82.86
Price Target39.78 (2825%)
EPS Next Y99.29%
Revenue Next YearN/A

BVXV Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

BVXV Financial Highlights

Over the last trailing twelve months BVXV reported a non-GAAP Earnings per Share(EPS) of -6.86. The EPS decreased by -93.48% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-10.92M
Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%45.5%
Sales Q2Q%N/A
EPS 1Y (TTM)-93.48%
Revenue 1Y (TTM)N/A

BVXV Ownership

Ownership
Inst Owners6.93%
Shares3.65M
Float3.55M
Ins Owners18.86%
Short Float %N/A
Short RatioN/A

BVXV Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO28.18921.899B
JNJ JOHNSON & JOHNSON20.74583.292B
MRK MERCK & CO. INC.22.34286.575B
PFE PFIZER INC8.9152.733B
BMY BRISTOL-MYERS SQUIBB CO9.33120.05B
ZTS ZOETIS INC16.3448.739B
RPRX ROYALTY PHARMA PLC- CL A8.8326.461B
VTRS VIATRIS INC5.3915.889B
ELAN ELANCO ANIMAL HEALTH INC21.8111.276B
AXSM AXSOME THERAPEUTICS INC N/A7.883B
BLTE BELITE BIO INC - ADR N/A6.361B
TERN TERNS PHARMACEUTICALS INC N/A4.698B
LGND LIGAND PHARMACEUTICALS23.94.217B

About BVXV

Company Profile

BVXV logo image BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.

Company Info

IPO: 2007-06-07

BIONDVAX PHARMACEUTICALS-ADR

Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus

JERUSALEM 74036 IL

CEO: Amir Reichman

Employees: 33

BVXV Company Website

Phone: 97289302529.0

BIONDVAX PHARMACEUTICALS-ADR / BVXV FAQ

What does BIONDVAX PHARMACEUTICALS-ADR do?

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.


What is the stock price of BIONDVAX PHARMACEUTICALS-ADR today?

The current stock price of BVXV is 1.36 USD. The price increased by 3.82% in the last trading session.


What is the dividend status of BIONDVAX PHARMACEUTICALS-ADR?

BVXV does not pay a dividend.


What is the ChartMill technical and fundamental rating of BVXV stock?

BVXV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the market capitalization of BVXV stock?

BIONDVAX PHARMACEUTICALS-ADR (BVXV) has a market capitalization of 4.97M USD. This makes BVXV a Nano Cap stock.


What is the ownership structure of BIONDVAX PHARMACEUTICALS-ADR (BVXV)?

You can find the ownership structure of BIONDVAX PHARMACEUTICALS-ADR (BVXV) on the Ownership tab.